 Ranitidine certain cellular immune responses asymptomatic HIV-infected individuals Human immunodeficiency virus HIV infection progressive impairment immunocompetence opportunistic infections malignancies double-blind placebo-controlled study potential impact immunomodulation oral ranitidine mg days HIV-positive patients CDC group II clinical signs infections agents Several immunological parameters HIV infection impaired early HIV infection Spontaneous vitro interferon-alpha-stimulated natural killer cell activity ranitidine-treated patients contrast decrease nontreated patients groups T-cell blastogenesis stimulation soluble receptors serum ranitidine-treated patients nontreated patients ranitidine treatment cell counts significant improvement immunocompetence study small present result need trials immunomodulation ranitidine HIV-infected individuals